Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

The FDA has approved an investigational device exemption (IDE) application for the start of a pilot study evaluating the ...

Uday R. Popat, MD, discusses promising findings from a phase 2 trial evaluating the JAK inhibitor itacitinib combined with ...

Panelists discuss how, when a patient progresses to second-line therapy, key considerations include prior treatment response, toxicity, patient comorbidities, and therapeutic goals. Lenvatinib shows ...

Marlise R. Luskin, MD, MSCE, discusses the vigilant monitoring required for capillary leak syndrome with tagraxofusp in BPDCN ...

Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...